8th Global Symposium on Ketogenic Therapies

第八届全球生酮疗法研讨会

• 批准号: 10753748
• 负责人: Jong Min Rho
• 金额: $ 2.5万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10753748
• 关键词: Adult; Advocacy; Alzheimer' s Disease; Anniversary; Anticonvulsants; Anxiety; Awareness; Basic Science; Bipolar Disorder; Brain; Budgets; California; Carbohydrates; Clinical; Clinical Investigator; Clinical Research; Cognition Disorders; Collaborations; Communities; Congresses; Country; Dedications; Diet and Nutrition; Diet therapy; Dietitian; Discipline; Disease; Dissemination and Implementation; Eastern Africa; Eastern Europe; Education; Educational workshop; Effectiveness; Eligibility Determination; Epilepsy; Fasting; Fatty Acids; Fatty acid glycerol esters; Fellowship; Fertilization; Formulation; Foundations; Funding; Future Generations; Glucose Transporter; Goals; Grant; Growth; Headache; International; Intractable Epilepsy; Ketone Bodies; Knowledge; Lead; Malignant - descriptor; Malignant neoplasm of brain; Mediator; Medical; Mental Depression; Mental Health; Mental disorders; Metabolic; Metabolism; Modernization; Multiple Sclerosis; Neurologic; Nurses; Parkinson Disease; Patients; Perception; Physicians; Postdoctoral Fellow; Pre-Clinical Model; Professional Organizations; Property; Proteins; Protocols documentation; Randomized; Recording of previous events; Research; Research Personnel; Resources; SLC2A1 gene; Schedule; Schizophrenia; Science; Scientist; Series; Sleep Disorders; Social Workers; Societies; Solid; Southeastern Asia; Standardization; Students; Syndrome; Therapeutic; Time; Training; Translational Research; Travel; United States National Institutes of Health; Variant; autism spectrum disorder; brain metabolism; chronic pain; clinical application; clinical efficacy; dietary; equity, diversity, and inclusion; experience; health application; innovation; interdisciplinary collaboration; interest; ketogenic diet; ketogentic; meetings; neglect; nervous system disorder; neuroprotection; novel; personalized care; posters; pre-clinical; programs; prospective; spinal cord and brain injury; success; symposium; treatment choice

PROJECT SUMMARY The ketogenic diet (KD) is an established medical therapy for drug-resistant epilepsy, and since its origins in 1921 has steadily grown in clinical importance and worldwide implementation. Moreover, the expanding research into the scientific underpinnings of this metabolism-based treatment have highlighted numerous novel mechanisms. Moreover, there is mounting experimental evidence for potential disease-modifying and neuroprotective properties of metabolic substrates such as ketone bodies and fatty acids, such that preclinical and clinical investigators have been exploring broader uses of the KD and its variants in diverse neurological (and even mental health) conditions such as malignant brain cancer, autism spectrum disorder, Alzheimer's disease, and bipolar disorder. Despite proven clinical efficacy and relative affordability compared to anti-seizure medications, large regions of the world still do not and cannot broadly offer KD therapies to eligible patients. Centers often have inadequate resources, as well as a lack of appropriately trained physicians and/or dietitians. Furthermore, the latest research findings may not be well disseminated, and a lack of standardized protocols and management strategies present additional barriers. Without adequate support or proper education, patients may not consider this treatment due to its traditional restrictiveness and myths surrounding its use. Regular regional and international meetings are needed where scientists, physicians, dietitians, nurses, social workers and trainees at all levels can meet and discuss and share protocols, research innovations, clinical experience and establish new collaborations in the growing KD field. The 8th Global Symposium on Ketogenic Therapies (to be held September 17-21, 2023 in San Diego, California) is the latest in a successful and evolving biennial conference series first launched in 2008 with support from a NIH R13 conference grant. There has been an enduring collaborative spirit with a common purpose that has now matured into a new professional society called the International Neurological Ketogenic Society or INKS. The 8th Global Symposium represents another leap forward: the focus remains on promoting collaborative interactions among clinical and basic scientists and trainees and disseminating the latest research to the community and beyond, and a strong emphasis will be placed on standardizing and enhancing international dissemination and implementation – all of this in the spirit of equity, diversity and inclusion. Moreover, this will be the first congress in the biennial series organized in conjunction with two aligned organizations, the Glucose Transporter Deficiency 1 (GLUT1) Foundation and the International Society of Neurogastronomy (ISN). The KD is the treatment of choice for the GLUT1 deficiency syndrome, and ISN's focus on the science and practice of flavor perception represents an often-neglected aspect of diet and nutrition that is central to compliance and success of dietary treatments. These symposia will remain the definitive venue for progress in and advocacy for metabolism-based therapies for neurological disorders.

项目摘要 生酮饮食（KD）是一种已建立的耐药性癫痫的药物治疗，既然起源于 1921年已经悄悄地在临床重要性和全球实施方面发展。而且，不断扩展的研究 进入这种基于新陈代谢的治疗的科学基础，突出了许多新颖的新型 机制。此外，还有越来越多的实验证据证明了潜在的疾病修饰和 代谢底物（例如酮体和脂肪酸）的神经保护特性，以至于临床前 临床研究人员一直在探索KD的广泛用途及其在潜水员中立的变体 （甚至是心理健康），例如恶性脑癌，自闭症谱系障碍，阿尔茨海默氏症 疾病和躁郁症。尽管与反塞兹相比，临床效率和相对可用性已得到证实 药物，世界上的大区域仍然没有，也不能为合格的患者提供KD疗法。 中心通常缺乏资源不足，缺乏经过适当培训的医师和/或营养师。 此外，最新的研究结果可能无法很好地传播，并且缺乏标准化协议 管理策略提出了其他障碍。没有足够的支持或适当的教育，患者 由于其传统限制性和围绕其使用的神话，可能不会考虑这种治疗方法。常规的 需要区域和国际会议，科学家，医师，营养师，护士，社会工作者需要 各级的受训者可以满足，讨论和分享协议，研究创新，临床经验 并在不断发展的KD领域建立新的合作。第八届全球生酮疗法研讨会（TO 2023年9月17日至21日在加利福尼亚州圣地亚哥举行）是成功且不断发展的双年展的最新活动 会议系列于2008年首次在NIH R13会议赠款的支持下启动。有一个 具有共同目的的持久协作精神，现在已经成熟成为一个名为的新专业社会 国际神经生酮社会或墨水。第八届全球研讨会代表了另一个飞跃 前锋：重点仍然放在促进临床和基础科学家之间的协作互动 和受训者，并将最新研究传播给社区及其他地区，并非常重视 将置于标准化和增强国际传播和实施方面 - 所有这些 本着公平，多样性和包容的精神。而且，这将是双年展系列中的第一个国会大会 葡萄糖转运蛋白缺陷1（GLUT1）与两个对齐组织结合组织 基金会和国际神经经济学学会（ISN）。 KD是选择的治疗 Glut1缺乏综合症，ISN对风味感知的科学和实践的关注代表 饮食和营养的经常被综合的方面，这是饮食治疗的依从性和成功的核心。这些 研讨会将仍然是基于代谢的疗法的进步和倡导的确切场所 神经系统疾病。